Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
Paul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
Mike Cordonnier, CEO, Carlsmed | Onyx Live | JPM 2026
Hundreds of thousands of spine fusions are performed each year, but implant choice is still often limited to standard sizes.
Chris Hall, CEO, Personalis | Onyx Live | JPM 2026
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
Adrian Gottschalk, CEO, Foghorn Therapeutics | Onyx Live | JPM 2026
The machinery that governs gene expression is being targeted to beat cancer.
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?
Nick Delmonico, CEO, Strados Labs | Onyx Live | JPM 2026
1 in 5 patients hospitalized with COPD are readmitted within 30 days of discharge - costing the US over $15 billion. But why?
How is AI changing biotech diligence? | Treehill Partners Ep. 1 | Onyx Live | JPM 2026
The status quo is over.